Who Paid My Doc
Stuart Weinerman
Endocrinology, Diabetes & Metabolism New Hyde Park, NY Medical Doctor
NPI 1376698159 CMS profile 289525
2800 Marcus Ave, New Hyde Park, NY 11042
General payments
$1,162
Research payments
$53,300
Ownership & investment interest
$0
Research they led as principal investigator
$88,396
Through program year 2025, Stuart Weinerman of New Hyde Park, NY is reported in the CMS Open Payments database as having received $1,162 across 6 general payments and $53,300 in research payments paid to them. Separately, studies naming them as principal investigator received $88,396 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $662 | 2 | |
| 2024 | Research | $8,693 | 5 | |
| 2023 | Research | $43,945 | 10 | |
| 2019 | General | $1,162 | 6 |
Beside peers
- Stuart Weinerman
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Stuart Weinerman were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Stuart Weinerman | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,162 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $0 | $398 | $88–$1,981 | $132 |
| 2022 | $0 | $364 | $88–$1,568 | $149 |
| 2023 | $0 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 33 drugsPart D claims
2,422
Drug cost
$634,398
Branded share of claims
24.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Prolia Denosumab | Brand | 120 | $206,013 | |
| Tymlos Abaloparatide | Brand | 38 | $122,078 | |
| Ozempic Semaglutide | Brand | 45 | $77,434 | |
| Trulicity Dulaglutide | Brand | 20 | $39,556 | |
| Risedronate Sodium | Generic | 354 | $37,413 | |
| Teriparatide | Generic | 13 | $33,303 | |
| Jardiance Empagliflozin | Brand | 14 | $23,970 | |
| Januvia Sitagliptin Phosphate | Brand | 17 | $19,131 | |
| Synthroid Levothyroxine Sodium | Brand | 185 | $14,306 | |
| Testosterone | Generic | 27 | $11,970 |
The 10 drugs with the highest cost, of 33 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 25 billing codesPaid by Medicare
$2,735,364
Medicare patients
1,771
Services billed
165,008
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Osteoporosis | 75% | |
| High blood pressure | 58% | |
| Arthritis | 51% | |
| Ischemic heart disease | 23% | |
| Cancer | 21% | |
| Diabetes | 19% | |
| Depression | 17% | |
| Atrial fibrillation | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 891 | 90,780 | $1,862,216 |
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 52 | 67,095 | $572,280 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
23 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in New York
Robert Busch
Endocrinology, Diabetes & Metabolism · Albany, NY
Michael Shanik
Endocrinology, Diabetes & Metabolism · Smithtown, NY
Ajay Chaudhuri
Endocrinology, Diabetes & Metabolism · Buffalo, NY
Vinay Kapoor
Endocrinology, Diabetes & Metabolism · Manhasset, NY
John Bilezikian
Endocrinology, Diabetes & Metabolism · New York, NY
Barbara Hirsch
Endocrinology, Diabetes & Metabolism · Manhasset, NY
Related records
Endocrinology, Diabetes & Metabolism in New York
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.